The added value of type I interferons to cytotoxic treatments of cancer

Laura Bracci, Antonella Sistigu, Enrico Proietti, Federica Moschella

Research output: Contribution to journalShort surveypeer-review


Type I interferons (IFNs) exert anti-proliferative, antiviral and immunomodulatory activities. They are also involved in cell differentiation and anti-tumor defense processes. A growing body of literature indicates that the success of conventional chemotherapeutics, epigenetic drugs, targeted anticancer agents and radiotherapy (RT) relies, at least in part, on the induction of type I IFN signaling in malignant cells, tumor-infiltrating antigen presenting cells or other immune cells within lymphoid organs or blood. The mechanisms underlying type I IFN induction and the clinical consequences of these observations are only beginning to be elucidated. In the present manuscript, we reviewed the recent advances in the field and provided our personal view on the role of type I IFNs induced in the context of cytotoxic anticancer treatments and on its possible exploitation as a complement in cancer therapy.

Original languageEnglish
Pages (from-to)89-97
Number of pages9
JournalCytokine and Growth Factor Reviews
Publication statusPublished - Aug 1 2017


  • Chemotherapy
  • Immunogenicity
  • Radiotherapy
  • Type I interferon

ASJC Scopus subject areas

  • Immunology
  • Endocrinology, Diabetes and Metabolism
  • Immunology and Allergy
  • Biochemistry, Genetics and Molecular Biology(all)


Dive into the research topics of 'The added value of type I interferons to cytotoxic treatments of cancer'. Together they form a unique fingerprint.

Cite this